Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVXNASDAQ:BNTCNASDAQ:CRBPNASDAQ:KMDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$6.05-0.2%$6.59$4.77▼$14.22$383.79M0.01155,101 shs186,573 shsBNTCBenitec Biopharma$14.94-3.2%$14.38$5.74▼$17.15$392.18M0.4443,778 shs270,605 shsCRBPCorbus Pharmaceuticals$8.31+0.4%$7.50$4.64▼$61.90$101.69M3.11347,221 shs68,090 shsKMDAKamada$7.22+1.1%$6.75$4.74▼$9.16$415.19M0.9494,289 shs60,954 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax0.00%-13.82%+4.31%-18.02%-54.58%BNTCBenitec Biopharma0.00%-6.16%+7.25%-7.26%+106.07%CRBPCorbus Pharmaceuticals0.00%-9.38%+9.78%+44.52%-81.03%KMDAKamada0.00%+4.03%+5.09%+7.44%+42.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABVXAbivax1.8866 of 5 stars3.52.00.00.00.00.80.6BNTCBenitec Biopharma2.4932 of 5 stars3.62.00.00.02.92.50.0CRBPCorbus Pharmaceuticals3.971 of 5 stars3.61.00.04.71.62.50.6KMDAKamada3.9328 of 5 stars3.43.00.00.03.11.73.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXAbivax 3.00Buy$31.00412.40% UpsideBNTCBenitec Biopharma 3.22Buy$23.8359.53% UpsideCRBPCorbus Pharmaceuticals 3.10Buy$50.88512.21% UpsideKMDAKamada 2.75Moderate Buy$14.67103.14% UpsideCurrent Analyst Ratings BreakdownLatest CRBP, ABVX, BNTC, and KMDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025BNTCBenitec BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.005/15/2025BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$20.00 ➝ $20.005/15/2025KMDAKamadaBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.005/8/2025KMDAKamadaSidotiSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold5/7/2025CRBPCorbus PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/7/2025CRBPCorbus PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$65.00 ➝ $58.005/7/2025CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$60.00 ➝ $56.005/7/2025CRBPCorbus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $40.004/30/2025ABVXAbivaxJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$33.00 ➝ $33.004/10/2025BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$18.00 ➝ $20.003/24/2025BNTCBenitec BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXAbivaxN/AN/AN/AN/A$0.69 per shareN/ABNTCBenitec Biopharma$80K4,902.19N/AN/A$4.68 per share3.19CRBPCorbus PharmaceuticalsN/AN/AN/AN/A$11.69 per shareN/AKMDAKamada$160.95M2.58$0.49 per share14.69$4.51 per share1.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXAbivax-$190.71MN/A0.00N/AN/AN/AN/AN/A8/11/2025 (Estimated)BNTCBenitec Biopharma-$21.75M-$1.51N/AN/AN/AN/A-38.26%-35.71%N/ACRBPCorbus Pharmaceuticals-$40.21M-$4.22N/AN/AN/AN/A-36.87%-32.87%8/5/2025 (Estimated)KMDAKamada$14.46M$0.2924.9022.560.889.60%6.31%4.43%8/13/2025 (Estimated)Latest CRBP, ABVX, BNTC, and KMDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q3 2025BNTCBenitec Biopharma-$0.36-$0.24+$0.12-$0.24N/AN/A5/14/2025Q1 2025KMDAKamada$0.07$0.07N/A$0.07$154.06 million$44.02 million5/6/2025Q1 2025CRBPCorbus Pharmaceuticals-$1.26-$1.39-$0.13-$1.39N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABVXAbivaxN/AN/AN/AN/AN/ABNTCBenitec BiopharmaN/AN/AN/AN/AN/ACRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/AKMDAKamadaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXAbivax1.291.251.25BNTCBenitec Biopharma0.0114.8014.80CRBPCorbus PharmaceuticalsN/A11.8211.82KMDAKamadaN/A3.301.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXAbivax47.91%BNTCBenitec Biopharma52.19%CRBPCorbus Pharmaceuticals64.64%KMDAKamada20.38%Insider OwnershipCompanyInsider OwnershipABVXAbivaxN/ABNTCBenitec Biopharma1.30%CRBPCorbus Pharmaceuticals3.60%KMDAKamada36.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXAbivax6163.44 millionN/ANot OptionableBNTCBenitec Biopharma2026.25 million25.91 millionNo DataCRBPCorbus Pharmaceuticals4012.24 million11.80 millionOptionableKMDAKamada36057.51 million36.75 millionOptionableCRBP, ABVX, BNTC, and KMDA HeadlinesRecent News About These CompaniesKamada Stock Price HistoryJune 19 at 7:53 AM | investing.comKMDA vs. ACAD: Which Stock Is the Better Value Option?June 18 at 12:41 PM | zacks.comShould Value Investors Buy Kamada (KMDA) Stock?June 18 at 11:20 AM | msn.comKamada Confirms Continuous Global Business Operations and Products Availability Despite Recent Events in the Middle EastJune 17 at 7:00 AM | globenewswire.comKamada Ltd. (NASDAQ:KMDA) Short Interest UpdateJune 15, 2025 | marketbeat.comDaichi Kamada Highlights Quality Gap Between Indonesian and Australian National TeamsJune 12, 2025 | en.tempo.coKamada nets brace in Japan rout as South Korea put four past KuwaitJune 10, 2025 | beinsports.comKamada hits double as Japan thrash Indonesia 6-0June 10, 2025 | msn.comImplied Volatility Surging for Kamada Stock OptionsJune 10, 2025 | msn.comFootball: Daichi Kamada, Takefusa Kubo spur Japan to big win over IndonesiaJune 10, 2025 | mainichi.jpMillennium Management LLC Sells 36,872 Shares of Kamada Ltd. (NASDAQ:KMDA)June 3, 2025 | marketbeat.comWall Street Analysts Think Kamada (KMDA) Could Surge 106.86%: Read This Before Placing a BetJune 2, 2025 | zacks.comAre Investors Undervaluing Kamada (KMDA) Right Now?June 2, 2025 | zacks.comKMDA vs. CSLLY: Which Stock Should Value Investors Buy Now?May 28, 2025 | zacks.comKamada (NASDAQ:KMDA) Stock Crosses Below 200 Day Moving Average - What's Next?May 28, 2025 | marketbeat.comHC Wainwright Issues Optimistic Outlook for Kamada EarningsMay 20, 2025 | marketbeat.comIs Kamada (KMDA) Stock Undervalued Right Now?May 16, 2025 | msn.comWall Street Analysts Believe Kamada (KMDA) Could Rally 106.56%: Here's is How to TradeMay 16, 2025 | msn.comCompared to Estimates, Kamada (KMDA) Q1 Earnings: A Look at Key MetricsMay 15, 2025 | msn.comKamada Ltd (KMDA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ExpansionMay 15, 2025 | finance.yahoo.comKamada Ltd. (NASDAQ:KMDA) Q1 2025 Earnings Call TranscriptMay 15, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRBP, ABVX, BNTC, and KMDA Company DescriptionsAbivax NASDAQ:ABVX$6.05 -0.01 (-0.17%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$6.04 0.00 (-0.08%) As of 06/18/2025 04:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Benitec Biopharma NASDAQ:BNTC$14.94 -0.50 (-3.24%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$14.94 0.00 (-0.03%) As of 06/18/2025 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.Corbus Pharmaceuticals NASDAQ:CRBP$8.31 +0.03 (+0.36%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$8.56 +0.25 (+3.01%) As of 06/18/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Kamada NASDAQ:KMDA$7.22 +0.08 (+1.12%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$7.28 +0.06 (+0.76%) As of 06/18/2025 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
